The STRIVE Phase 2 study evaluated the safety, tolerability and efficacy of once-weekly dosing of rezafungin (RZF) compared to once-daily dosing of caspofungin (CAS) in patients with candidemia and/or invasive candidiasis. The study evaluated two IV dosing regimens of either 400 mg of rezafungin administered once weekly (400/400) or 400 mg on week one, then 200 mg once weekly thereafter (400/200). For the primary endpoint, the RZF 400/200 mg group had a higher rate of overall cure at day 14 compared with other groups. For the secondary endpoint of all-cause mortality (ACM) at day 30, the lowest rate observed was in the RZF 400/200 mg group. True cure rates with indeterminate responses excluded, such as for the primary efficacy endpoint of overall response, were 81.4% for RZF 400/200 mg, 69.7% for rezafungin 400 mg, and 70.7% for CAS. Rezafungin demonstrated superiority on time to negative blood culture compared to caspofungin (log-rank test combining both rezafungin groups vs. caspofungin, p = 0.02).